ImmunoPrecise Antibodies Management
Management criteria checks 2/4
ImmunoPrecise Antibodies' CEO is Jennifer Bath, appointed in Feb 2018, has a tenure of 6.75 years. total yearly compensation is CA$1.01M, comprised of 72.8% salary and 27.2% bonuses, including company stock and options. directly owns 0.9% of the company’s shares, worth €93.44K. The average tenure of the management team and the board of directors is 3.3 years and 1.2 years respectively.
Key information
Jennifer Bath
Chief executive officer
CA$1.0m
Total compensation
| CEO salary percentage | 72.8% |
| CEO tenure | 6.8yrs |
| CEO ownership | 0.9% |
| Management average tenure | 3.3yrs |
| Board average tenure | 1.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jul 31 2024 | n/a | n/a | -CA$28m |
| Apr 30 2024 | CA$1m | CA$732k | -CA$27m |
| Jan 31 2024 | n/a | n/a | -CA$14m |
| Oct 31 2023 | n/a | n/a | -CA$16m |
| Jul 31 2023 | n/a | n/a | -CA$21m |
| Apr 30 2023 | CA$2m | CA$714k | -CA$27m |
| Jan 31 2023 | n/a | n/a | -CA$26m |
| Oct 31 2022 | n/a | n/a | -CA$25m |
| Jul 31 2022 | n/a | n/a | -CA$23m |
| Apr 30 2022 | CA$2m | CA$649k | -CA$17m |
| Jan 31 2022 | n/a | n/a | -CA$17m |
| Oct 31 2021 | n/a | n/a | -CA$15m |
| Jul 31 2021 | n/a | n/a | -CA$10m |
| Apr 30 2021 | CA$2m | CA$503k | -CA$7m |
| Jan 31 2021 | n/a | n/a | -CA$3m |
| Oct 31 2020 | n/a | n/a | -CA$3m |
| Jul 31 2020 | n/a | n/a | -CA$3m |
| Apr 30 2020 | CA$673k | CA$488k | -CA$5m |
| Jan 31 2020 | n/a | n/a | -CA$8m |
| Oct 31 2019 | n/a | n/a | -CA$8m |
| Jul 31 2019 | n/a | n/a | -CA$9m |
| Apr 30 2019 | CA$1m | CA$505k | -CA$8m |
| Jan 31 2019 | n/a | n/a | -CA$6m |
| Oct 31 2018 | n/a | n/a | -CA$6m |
| Jul 31 2018 | n/a | n/a | -CA$5m |
| Apr 30 2018 | CA$65k | CA$65k | -CA$5m |
Compensation vs Market: Jennifer's total compensation ($USD719.06K) is above average for companies of similar size in the German market ($USD471.55K).
Compensation vs Earnings: Jennifer's compensation has been consistent with company performance over the past year.
CEO
Jennifer Bath
6.8yrs
Tenure
CA$1,005,342
Compensation
Dr. Jennifer Lynne Bath, Ph D, has been the Chief Executive Officer and President of ImmunoPrecise Antibodies Ltd. since February 21, 2018.Dr. Bath served as the Global Director of Client Relations at Ald...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Non-Independent Director | 6.8yrs | CA$1.01m | 0.90% € 93.4k | |
| Chief Financial Officer | 1.2yrs | CA$865.30k | 0.069% € 7.2k | |
| Chief Scientific Officer & Interim General Manager of IPA Europe | 3.3yrs | CA$276.93k | 0.033% € 3.4k | |
| Vice President of Commercial Services | no data | CA$273.60k | no data | |
| Head of General Operations of the Utrecht site of IPA (Europe) | no data | no data | no data |
3.3yrs
Average Tenure
Experienced Management: TQB's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Non-Independent Director | 6.5yrs | CA$1.01m | 0.90% € 93.4k | |
| Independent Director | less than a year | CA$108.91k | 0.10% € 10.7k | |
| Independent Director | 1.2yrs | CA$118.45k | no data | |
| Member of Strategic Advisory Board | 3.5yrs | no data | no data | |
| Independent Chairman of the Board | 1.2yrs | CA$117.69k | 0.0068% € 698.3 |
1.2yrs
Average Tenure
Experienced Board: TQB's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.